YU16600A - Farmaceutske smeše koje sadrže plazma-protein - Google Patents
Farmaceutske smeše koje sadrže plazma-proteinInfo
- Publication number
- YU16600A YU16600A YU16600A YU16600A YU16600A YU 16600 A YU16600 A YU 16600A YU 16600 A YU16600 A YU 16600A YU 16600 A YU16600 A YU 16600A YU 16600 A YU16600 A YU 16600A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- plasma protein
- pharmaceutical composition
- composition containing
- containing plasma
- active substance
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 108010017384 Blood Proteins Proteins 0.000 title abstract 2
- 102000004506 Blood Proteins Human genes 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010058237 plasma protein fraction Proteins 0.000 abstract 1
- 229940081857 plasma protein fraction Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Ovaj pronalazak se odnosi na, u vodi rastvorne, proizvode i farmaceutske formulacije u čvrstom ili tečnom obliku uglavnom za parenteralnu primenu. Oni se sastoje od ili obuhvataju terapeutski aktivnu supstancu (koja ima malu rastvorljivost u vodi i znatan afinitet vezivanja za plazma proteine) i frakciju plazma proteina u kontrolisanom stanju agregacije, pri čemu su pomenuta aktivna supstanca i pomenuta proteinska frakcija vezane jedna za drugu pomoću nekovalentnih veza. Ovaj pronalazak takodje pokriva postupke za dobivanje ovog proizvoda i farmaceutske formulacije.[The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of noncovalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9701554A HUP9701554D0 (en) | 1997-09-18 | 1997-09-18 | Pharmaceutical composition containing plazma proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
YU16600A true YU16600A (sh) | 2003-08-29 |
RS50102B RS50102B (sr) | 2009-01-22 |
Family
ID=90014222
Country Status (33)
Country | Link |
---|---|
US (5) | US6743826B1 (sh) |
EP (1) | EP0981375B1 (sh) |
JP (1) | JP2001508806A (sh) |
KR (1) | KR100587962B1 (sh) |
CN (1) | CN1189216C (sh) |
AR (1) | AR017120A1 (sh) |
AT (1) | ATE230611T1 (sh) |
AU (1) | AU734695B2 (sh) |
BG (1) | BG64749B1 (sh) |
BR (1) | BR9812469A (sh) |
CA (1) | CA2269923C (sh) |
CZ (1) | CZ301326B6 (sh) |
DE (1) | DE69810612T2 (sh) |
DK (1) | DK0981375T3 (sh) |
EA (1) | EA004700B1 (sh) |
ES (1) | ES2187062T3 (sh) |
HR (1) | HRP980499A2 (sh) |
HU (1) | HUP9701554D0 (sh) |
IL (1) | IL135055A (sh) |
LT (1) | LT4736B (sh) |
LV (1) | LV12493B (sh) |
NO (1) | NO325294B1 (sh) |
NZ (1) | NZ503302A (sh) |
PL (1) | PL193067B1 (sh) |
PT (1) | PT981375E (sh) |
RO (1) | RO118695B1 (sh) |
RS (1) | RS50102B (sh) |
SI (1) | SI20189B (sh) |
SK (1) | SK284683B6 (sh) |
TR (1) | TR200001545T2 (sh) |
TW (1) | TWI222365B (sh) |
WO (1) | WO1999013914A1 (sh) |
ZA (1) | ZA988585B (sh) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
WO2000047187A1 (en) * | 1999-02-11 | 2000-08-17 | Kinetana Inc. | Serum albumin-based parenteral formulations of polyene macrolides |
AU781994B2 (en) | 1999-09-16 | 2005-06-23 | Novo Nordisk A/S | Composition for IVF |
WO2001076559A1 (en) * | 2000-04-10 | 2001-10-18 | Teva Pharmaceutical Industries Ltd. | Method 0f administration of paclitaxel-plasma protein formulation |
CN1438882A (zh) * | 2000-04-10 | 2003-08-27 | 特瓦制药工业有限公司 | 施用诱导细胞凋亡的化疗剂治疗癌症的方法和组合物 |
WO2002087563A2 (en) * | 2001-05-01 | 2002-11-07 | Angiotech Pharmaceuticals Inc. | Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
PL375363A1 (en) | 2002-07-16 | 2005-11-28 | Medexis S.A. | Steroid conjugates, preparation thereof and the use thereof |
GR1004274B (el) | 2002-07-16 | 2003-06-23 | Medexis ���� | Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες |
WO2004024188A1 (ja) * | 2002-09-12 | 2004-03-25 | Nihon Medi-Physics Co., Ltd. | 薬物の血漿蛋白質結合を制御するための製剤 |
CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
US20050079546A1 (en) * | 2003-05-01 | 2005-04-14 | Dasa Lipovsek | Serum albumin scaffold-based proteins and uses thereof |
US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
US20050277584A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
WO2006035443A2 (en) * | 2004-09-29 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Monitoring of convection enhanced drug delivery |
US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
ES2393814T3 (es) | 2007-04-04 | 2012-12-28 | Sigmoid Pharma Limited | Una composición farmacéutica oral |
WO2008132707A1 (en) | 2007-04-26 | 2008-11-06 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
US20110009497A1 (en) * | 2008-03-21 | 2011-01-13 | Fujifilm Corporation | Drug-containing composition |
CN101658516B (zh) * | 2008-08-26 | 2011-10-05 | 齐鲁制药有限公司 | 紫杉醇类药物组合物及其制备方法 |
DK2471518T3 (en) | 2009-05-18 | 2017-12-04 | Sigmoid Pharma Ltd | COMPOSITION INCLUDING OIL DROPS |
IN2012DN00781A (sh) | 2009-08-12 | 2015-06-26 | Sigmoid Pharma Ltd | |
EP2480209A1 (en) | 2009-09-23 | 2012-08-01 | Indu Javeri | Methods for the preparation of liposomes comprising docetaxel |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
BR112012014962A2 (pt) * | 2009-12-18 | 2016-04-05 | Exodos Life Sciences Ltd Partnership | métodos e composições para formulações líquidas e estáveis de fármacos |
US9333189B2 (en) * | 2010-02-03 | 2016-05-10 | Oncbiomune, Inc. | Taxane- and taxoid-protein compositions |
AR093275A1 (es) | 2010-03-17 | 2015-05-27 | Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
WO2015140736A1 (en) | 2014-03-18 | 2015-09-24 | Izun Pharmaceuticals Corp. | Protein-bound cannabinoid compositions |
EP3881829A1 (en) | 2014-11-07 | 2021-09-22 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
AR100034A1 (es) | 2015-01-30 | 2016-09-07 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas |
WO2016182929A1 (en) | 2015-05-08 | 2016-11-17 | Spectral Platforms, Inc. | Albumin-based non-covalent complexes and methods of use thereof |
CN107683134B (zh) | 2015-05-15 | 2021-02-23 | 珠海贝海生物技术有限公司 | 多西他赛及人血清白蛋白复合物 |
US20180185308A1 (en) * | 2015-06-18 | 2018-07-05 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating inflammatory disease or conditions |
US20170128480A1 (en) * | 2015-11-09 | 2017-05-11 | Max A. Cayo | Cardiac Glycosides for the Treatment of Hypercholesterolemia |
WO2018027029A1 (en) * | 2016-08-03 | 2018-02-08 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of fosaprepitant and aprepitant |
CN115487312A (zh) | 2016-10-27 | 2022-12-20 | 珠海贝海生物技术有限公司 | 多西他赛和人血清白蛋白的中性pH组合物 |
US12016838B2 (en) | 2017-03-09 | 2024-06-25 | Day Three Labs Manufacturing Inc. | Stabilized protein-bound cannabinoid compositions |
JP7134995B2 (ja) | 2017-03-20 | 2022-09-12 | スペクトラル プラットフォームス インコーポレイテッド | 微生物を検出し特徴づけるための分光法 |
IL271777B2 (en) | 2017-07-07 | 2024-09-01 | Epicentrx Inc | Preparations for intravenous administration of medical substances |
JP7081850B2 (ja) * | 2018-03-09 | 2022-06-07 | パノプテス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼科用製剤 |
EP3811982A1 (en) * | 2019-10-25 | 2021-04-28 | Université de Strasbourg | Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof |
CN111529506B (zh) * | 2020-05-18 | 2021-09-03 | 同济大学 | 一种两性霉素b白蛋白纳米制剂及其制备方法和应用 |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
JP7497448B2 (ja) * | 2021-06-29 | 2024-06-10 | ジンセル・バイオテック・インコーポレイテッド | アルブミンを高効率に生産する植物細胞株及びその用途 |
CN114544926A (zh) * | 2021-12-02 | 2022-05-27 | 浙江鑫科医疗科技有限公司 | 一种血清蛋白稳定剂 |
CN115236216B (zh) * | 2022-06-07 | 2024-03-01 | 合肥和合医疗科技有限公司 | 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒,其制备方法和检测方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4833013A (sh) * | 1971-08-30 | 1973-05-07 | ||
DE2653534C2 (de) * | 1975-12-22 | 1986-08-28 | Baxter Travenol Laboratories, Inc., Deerfield, Ill. | Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung |
JPS58216126A (ja) * | 1982-06-11 | 1983-12-15 | Ono Pharmaceut Co Ltd | 可容化製剤 |
DE3702105A1 (de) * | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
US5051406A (en) * | 1987-03-04 | 1991-09-24 | Nippon Hypox Laboratories Incorporated | Pharmaceutical composition using albumin as a carrier and process for producing the same |
JPS63215640A (ja) * | 1987-03-04 | 1988-09-08 | Nippon Hai Potsukusu:Kk | 易吸収性抗炎症剤及びその製造方法 |
CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
US5356927A (en) * | 1992-12-02 | 1994-10-18 | Thomas Jefferson University | Methods of treating plasmodium and babesia parasitic infections |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
GB9510716D0 (en) * | 1995-05-26 | 1995-07-19 | Pharmacia Spa | Substituted camptothecin derivatives and process for their preparation |
TR199600775A2 (tr) | 1996-09-27 | 1997-09-21 | Tureks Turunc Madencilik Ic Ve | Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem. |
US5776912A (en) * | 1996-12-20 | 1998-07-07 | Schering Corporation | Lipophilic oligosaccharide antibiotic compositions |
HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
-
1997
- 1997-09-18 HU HU9701554A patent/HUP9701554D0/hu unknown
-
1998
- 1998-09-10 HR HRP9701554A patent/HRP980499A2/hr not_active Application Discontinuation
- 1998-09-17 SI SI9820067A patent/SI20189B/sl active Search and Examination
- 1998-09-17 CN CNB988092514A patent/CN1189216C/zh not_active Expired - Fee Related
- 1998-09-17 EA EA200000331A patent/EA004700B1/ru not_active IP Right Cessation
- 1998-09-17 CA CA002269923A patent/CA2269923C/en not_active Expired - Lifetime
- 1998-09-17 DE DE69810612T patent/DE69810612T2/de not_active Expired - Lifetime
- 1998-09-17 RS YUP-166/00A patent/RS50102B/sr unknown
- 1998-09-17 KR KR1020007002810A patent/KR100587962B1/ko not_active IP Right Cessation
- 1998-09-17 ES ES98946629T patent/ES2187062T3/es not_active Expired - Lifetime
- 1998-09-17 BR BR9812469-2A patent/BR9812469A/pt not_active Application Discontinuation
- 1998-09-17 PL PL339369A patent/PL193067B1/pl unknown
- 1998-09-17 NZ NZ503302A patent/NZ503302A/en unknown
- 1998-09-17 WO PCT/HU1998/000086 patent/WO1999013914A1/en not_active Application Discontinuation
- 1998-09-17 DK DK98946629T patent/DK0981375T3/da active
- 1998-09-17 RO ROA200000315A patent/RO118695B1/ro unknown
- 1998-09-17 CZ CZ20000952A patent/CZ301326B6/cs not_active IP Right Cessation
- 1998-09-17 SK SK329-2000A patent/SK284683B6/sk not_active IP Right Cessation
- 1998-09-17 IL IL13505598A patent/IL135055A/en not_active IP Right Cessation
- 1998-09-17 AU AU93623/98A patent/AU734695B2/en not_active Ceased
- 1998-09-17 AT AT98946629T patent/ATE230611T1/de active
- 1998-09-17 PT PT98946629T patent/PT981375E/pt unknown
- 1998-09-17 EP EP98946629A patent/EP0981375B1/en not_active Expired - Lifetime
- 1998-09-17 TR TR2000/01545T patent/TR200001545T2/xx unknown
- 1998-09-17 JP JP51757699A patent/JP2001508806A/ja not_active Withdrawn
- 1998-09-18 TW TW087115619A patent/TWI222365B/zh not_active IP Right Cessation
- 1998-09-18 AR ARP980104659A patent/AR017120A1/es not_active Application Discontinuation
- 1998-09-18 ZA ZA9808585A patent/ZA988585B/xx unknown
-
1999
- 1999-04-27 US US09/299,562 patent/US6743826B1/en not_active Expired - Lifetime
-
2000
- 2000-03-14 LV LVP-00-38A patent/LV12493B/en unknown
- 2000-03-16 NO NO20001371A patent/NO325294B1/no not_active IP Right Cessation
- 2000-03-16 BG BG104245A patent/BG64749B1/bg unknown
- 2000-03-17 LT LT2000018A patent/LT4736B/lt not_active IP Right Cessation
-
2003
- 2003-01-21 US US10/349,492 patent/US7119124B2/en not_active Expired - Lifetime
-
2004
- 2004-03-17 US US10/802,528 patent/US7501455B2/en not_active Expired - Fee Related
-
2006
- 2006-10-10 US US11/546,518 patent/US20070232536A1/en not_active Abandoned
-
2009
- 2009-02-09 US US12/322,997 patent/US8946167B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU16600A (sh) | Farmaceutske smeše koje sadrže plazma-protein | |
BR9913857A (pt) | Formulações de proteìna | |
TW366286B (en) | Flavour-masked pharmaceutical compositions | |
WO2005007185A3 (de) | Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa) | |
WO2002051390A3 (en) | Amphiphilic lipid nanoparticles for peptide and/or protein incorporation | |
EP1025840A3 (en) | Oral drug compositions and methods | |
JO3404B1 (ar) | تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين | |
WO2001017548A3 (de) | Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen | |
CA2252772A1 (en) | Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents | |
EP1175909A3 (en) | Therapeutic methods and compositions based on serrate proteins and nucleic acids | |
EP1218368A4 (en) | Compositions and Methods for Modulating Apoptosis in Cells Expressing BC1-2 Family Proteins | |
EE03923B1 (et) | S-omeprasool neutraalsel kujul, selle valmistamise protsess ja seda sisaldavad ravimsegud | |
AU1887999A (en) | Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them | |
WO2000012542A3 (en) | Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties | |
HUP0002404A3 (en) | Amino acid derivatives, pharmaceutical compositions comprising thereof, process for preparation them and their use | |
WO1999059609A3 (en) | Use of hmg proteins for the preparation of medicaments having cytotoxic activity | |
WO2001034641A3 (en) | Antimicrobial activity of the first cationic cluster of human lactoferrin | |
WO2002044197A3 (en) | Cytokine receptor binding peptides | |
WO2000042031A3 (en) | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | |
AU7216498A (en) | Inhibitors of the urokinase receptor | |
EP0786256A3 (en) | Obesity protein formulations | |
EP0784981A3 (en) | Obesity protein formulations | |
AU2003224107A1 (en) | Soluble composition containing sporopollenin and the use thereof | |
EP1174439A3 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
EP0341661A3 (en) | Peptide-drug compositions containing alpha-aminoboronic acid derivatives |